Neptune posts 31% rise in nutraceutical sales in Q4 as krill oil demand grows
date:May 29, 2012
opharm businesses were up 15% to $19.12m while net losses increased to $4.59m compared with a $1.69m net loss for fiscal 2011.

Corporate reorganization

Neptune also announced a series of management changes that are in part, designed to put greater emphasis on stimulating sales growth, assessing our business portfolio opportunities and expanding operating profit margins, said president and chief executive Henri Harland.

These include:
Harland Waksal'snomination to the board of directors.


2/7 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/09 08:42